Clearside Biomedical’s Suprachoroidal Injection Platform Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society
- Presentations highlighted data analyses across multiple disease states -
- New, nonclinical data indicates potential for suprachoroidal administration of gene-based therapies -
Dr.
“With the submission of our new drug application for XIPERE™, we are working to build awareness of the broad potential of our suprachoroidal injection platform within the physician community. While our first potential commercial indication is in uveitic macular edema, we plan to expand to other areas within uveitis, diabetic macular edema, and gene therapy. We are grateful for the support of these investigators who presented the data demonstrating the potential of our platform in multiple settings,” added
Presentation:
Dr. Szilard Kiss, Director of Clinical Research, Associate Professor of Ophthalmology,
Title: | A new approach to ocular gene therapy: Evaluation of suprachoroidal administration of non-viral DNA nanoparticles in a rabbit model |
Summary:
Suprachoroidal administration of ellipsoid luciferase non-viral DNA nanoparticles (“DNPs”) produced activity that was comparable to that seen from subretinal injections, and significantly greater than that seen from the negative control or untreated eyes. Suprachoroidally injected DNPs were well tolerated, showed luciferase expression/activity in the choroid and retina of rabbit eyes, and provided preliminary evidence of the potential for suprachoroidal administration of gene-based therapies. Specifically, suprachoroidal administration may offer targeted delivery of gene therapies without risks of vitrectomy and subretinal administration.
Presentation:
Dr.
Title: | Suprachoroidal CLS-TA Plus Aflibercept Compared to Aflibercept Monotherapy for Diabetic Macular Edema: Results of the Randomized Phase 2 TYBEE Trial |
Summary:
Therapy of suprachoroidal CLS-TA and aflibercept showed similar visual and anatomic outcomes compared to aflibercept monotherapy for the treatment of DME. Combination dosing was associated with a meaningful reduction in treatment burden. Ocular adverse events were low for both arms.
Presentation:
Dr.
Title: | Suprachoroidal CLS-TA Improves Visual Acuity and Macular Edema in Noninfectious Uveitis: Results of the Phase 3 PEACHTREE Study |
Summary:
In this pivotal, 6-month, Phase 3 trial in subjects with uveitic macular edema of any anatomic location, suprachoroidal injection of CLS-TA met its primary endpoint (47% of subjects gaining 3-lines or greater in BCVA) when compared to sham control, while also demonstrating an acceptable safety profile.
Presentation:
Dr.
Title: | Suprachoroidally Injected CLS-TA Results in Rapid and Sustained Resolution of Macular Edema in a Majority of Uveitis Patients: Results of the AZALEA, DOGWOOD, and PEACHTREE Studies |
Summary:
These clinical trials consistently demonstrated that treatment of uveitic macular edema with suprachoroidally injected CLS-TA was associated with rapid improvement in macular edema that was sustained through study completion. The suprachoroidal approach offers the potential to more precisely target chorioretinal tissues and facilitate the treatment of visual loss in patients with uveitic macular edema.
These presentations are available on Clearside’s website in the Science section under Programs (http://www.clearsidebio.com/programs.htm#SCIENCE).
About XIPERE
XIPERE (triamcinolone acetonide suprachoroidal injectable suspension), formerly known as CLS-TA, is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via suprachoroidal injection for the treatment of macular edema associated with uveitis. Clearside’s patented technology is designed to deliver drug to the suprachoroidal space located between the choroid and the outer protective layer of the eye, known as the sclera. Suprachoroidal injection enables the rapid and adequate dispersion of medicine to the back of the eye offering the potential for the medicine to act longer and minimize harm to the surrounding healthy parts of the eye, thus potentially providing advantageous and sustained efficacy with a favorable safety profile. A New Drug Application (“NDA”) was submitted to the
About
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of Clearside’s product candidates, the potential attributes and benefits of Clearside’s product candidates, and the potential approval and commercialization of XIPERE in
Investor and Media Contacts:
ir@clearsidebio.com
Source:
Source: Clearside Biomedical, Inc.